Enable Injections upgrades the board with the addition of John DeFord, Ph.D.

new director, John DeFordPh.D., adds global medical technology experience to Enable Injections, furthering its mission as a global leader in drug delivery innovation.

CINCINNATI, August 11, 2022 /PRNewswire/ — Activate Injections, Inc. (“Enable”), a company developing and manufacturing the enFuse® experimental wearable drug delivery system platform, is pleased to announce the appointment of John DeForddoctorate to the company’s board of directors, effective July 29, 2022.

enFuse from Enable Injections is an innovative drug delivery technology designed to deliver large volumes of up to 50ml subcutaneously (SC) for a wide range of therapies and diseases, dedicated to improving the patient’s experience.

Dr. DeFord brings more than three decades of expertise as a global medical technology executive, most recently Executive Vice President and Chief Technology Officer of Becton, Dickinson and Company (BD) (BDX), a global technology company medical. Prior to BD, Dr. DeFord held positions of increasing responsibility in science, technology, and leadership at organizations such as CR Bard and Cook Incorporated, with additional experience in venture capital as a managing director of the venture capital fund Early Stage Partners. He is currently also a member of the board of directors of Nordson Corporation (NDSN), NuVasive (NUVA) and Blue Spark, Inc. DeFord is a graduate of Purdue University holds a bachelor’s and master’s degree in electrical engineering and a doctorate. in Electrical/Biomedical Engineering, dedicating his career to innovative medical technologies to save lives, improve quality of life and improve patient experience.

“Enable Injections is at the forefront of simplifying therapeutic delivery of critical medications and improving patient quality of life,” said Dr. DeFord. “I am delighted to join the Board of Directors at this important time in the growth and development of the company; and I look forward to working with the leadership team and board to help accelerate the translation of this important technology into the clinical setting. »

“We are thrilled to welcome Dr. DeFord as a new director to Enable’s Board of Directors,” said Mike Hooven, President and CEO of Enable Injections. “We believe that adding deep experience in the global medical technology space, like that of Dr. DeFord, is key to the strong growth of our business.”

About Enabling Injections

CincinnatiEnable Injections is a global healthcare innovation company that develops and manufactures drug delivery systems designed to improve the patient experience. EnFuse worn on Enable’s body® provides high-volume pharmaceutical and biologic therapeutics by subcutaneous administration, with the goal of improving convenience, supporting superior outcomes and advancing healthcare system economics. For more information, please visit www.enableinjections.com.

SOURCE Enable Injections, Inc.